LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end
Barchart Research What to Expect from ADCT Earnings ADCT Generated May 1, 2026 Current Price $3.83 EPS Estimate $$-0.19 Consensus Rating Strong Buy Average Move 10.96% ADC Therapeutics Reports Monday With...
Barchart Research What to Expect from ADCT Earnings ADCT Generated May 1, 2026 Current Price $3.83 EPS Estimate $$-0.19 Consensus Rating Strong Buy Average Move 10.96% ADC Therapeutics Reports Monday With...
Barchart Research What to Expect from ADCT Earnings ADCT Generated May 1, 2026 Current Price $3.83 EPS Estimate $$-0.19 Consensus Rating Strong Buy Average Move 10.96% ADC Therapeutics Reports Monday With...
LAUSANNE, Switzerland , May 1, 2026 /PRNewswire/ --Â ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...
LAUSANNE, Switzerland , April 27, 2026 /PRNewswire/ --Â ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...
LAUSANNE, Switzerland , April 1, 2026 /PRNewswire/ --Â ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...
LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026
LAUSANNE, Switzerland , March 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...
LAUSANNE, Switzerland , March 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...